Abstract
Introduction
Hepatocellular carcinoma (HCC) is a dreaded complication of liver cirrhosis, which accounts for approximately 800,000 deaths annually worldwide [1] . The median survival after diagnosis ranges from 6 to 20 months. The high case fatality rate reflects the relentless nature of the disease, which typically invades locally and frequently recurs after treatment. Macrovascular invasion indicates an aggressive disease phenotype and is seen in as many as 35% of the patients [2] . Inferior vena cava (IVC) invasion portends a very poor prognosis, with a mean survival time < 3 months [3] . Resection is increasingly being utilized for patients with IVC metastasis by experienced surgeons in high-incidence regions, but this remains a contraindication to surgery at many institutions. Multifocal disease and poor hepatic reserve due to cirrhosis or large tumor burden remain as barriers to surgical intervention. Additionally, quality of life concerns for patients unlikely to achieve curative resection may factor into a risk/benefit stratification. Resection of great vessel HCC metastasis is a high-risk surgery; many patients will not be acceptable candidates. Some may elect for a palliative approach; however, HCC is notoriously unresponsive to systemic therapies. This article details a novel palliative technique, which may prolong survival in patients with intrahepatic IVC invasion while preserving their quality of life.
Percutaneous cryoablation (PC) is a minimally invasive modality increasingly utilized for the treatment of primary and metastatic neoplastic lesions. Advantages of PC include intrinsic analgesic properties [4] , intraoperative imaging surveillance of the ablation zone [5] , potential for tumor-antigen-specific immune response [6] , versatility in targeting surgically inaccessible malignancy [7] , and tolerability for poor surgical candidates [8] . PC achieves cytoreduction of the tumor burden through a combination of membrane rupture due to crystal formation at the center of the ice ball and apoptosis at the periphery where freeze rates are insufficient to disrupt membrane integrity. Post-thaw ischemia also contributes to cell death: microvasculature up to 180 μm in diameter is obliterated by PC [9] . Larger vessels within the ablation zone are initially patent, although likely irreparably damaged. Two weeks after cryoablation, a flow void is seen on intravenous contrast-enhanced imaging studies [10] . This may be due to freezing-induced endothelial damage and thrombosis, occurring even in the 5-to-10-mm periphery of the ice ball, which fails to reach cytotoxic temperatures [11] .
Major vascular structures, such as the aorta, superior vena cava (SVC), and IVC, however, appear to be protected by heat dissipation due to brisk flow. This is known as the "thermal sink" effect. Histologic analyses following cryoablative insult have shown initial endothelial and smooth muscle cell death with maintenance of vessel patency through preserved elastin fibers. A single layer of platelets binds to these exposed fibers, which are replaced after about 1 week by migrating endothelial cells from adjacent areas. Smooth muscle regeneration occurs after about 2 weeks through subendothelial migration and subsequent proliferation, and complete repair is evident after around 1 month [12] . The "thermal sink" effect has been postulated to account for local cancer recurrence due to inadequate treatment adjacent to major vascular structures [13, 14] . Emerging techniques have been described in the literature, but until now, none have been able to confidently conquer this problem. We describe a technique using a large angioplasty balloon causing temporary cessation of the blood flow to allow intravascular cyroablation of a tumor extension within the intrahepatic IVC.
Materials and Methods
The patient was a 56-year-old female with hepatitis C and liver cirrhosis who initially presented with a 7-cm HCC in segment 4, as well as several smaller satellite lesions. The tumor was deemed unresectable, she was not a transplant candidate, and she refused systemic therapy. Life expectancy was initially determined to be < 3 months at multidisciplinary tumor board meetings. She was referred to interventional radiology and underwent 3 transarterial chemoembolizations, followed by 3 hepatic cryoablations over the course of several years with adequate ablation. Recurrent disease was subsequently identified on surveillance imaging and found to be invading the intrahepatic IVC (Fig. 1a-c) . Moderate sedation was utilized in the performance of this procedure. Pre-and postsedation patient evaluation, administration of the sedative and analgesic agents, and monitoring of the cardiorespiratory function were performed with the assistance of an independent, trained observer.
After appropriate informed consent was obtained, the patient was placed supine on the angiography table. The right groin was prepared and draped in a sterile fashion. The skin overlying the common femoral vein was then anesthetized with lidocaine. Access was obtained to the common femoral vein using a singlewall technique, and a guidewire was introduced into the IVC. Over the guidewire, a Q50 balloon catheter (W.L. Gore, Flagstaff, AZ, USA) was introduced into the IVC between the renal vein confluence and the intrahepatic segment, and a venogram was performed via the balloon catheter. This demonstrated a filling defect consistent with intraluminal tumor within the intrahepatic segment of the IVC; no filling defects were identified in the infra-/suprahepatic IVC (Fig. 2a) . The patient was then transported to the computed tomography (CT) scanner, positioned supine on the CT gantry, and the right upper quadrant abdomen was prepared and draped in the usual sterile fashion. Limited CT images were performed to delineate the liver mass and for procedure planning. Additional images were obtained following the administration of intravenous contrast via the previously placed catheter for delineation of the intravascular tumor. The skin was marked. Using CT guidance, three 17-gauge cryoablation probes were inserted using direct CT fluoroscopy into the liver mass bracketing the tumor, one in the superior 
Results
The patient tolerated the procedure well without immediate complications. Following completion of the procedure, the patient was admitted for overnight observation and pain control, and was discharged the next day. Follow-up imaging at 7 months after the procedure demonstrated continued decrease in the size of the tumor and no treatment-related complications (Fig. 3a-c) . The patient survived 9 months after the procedure with a good quality of life. She was able to travel with her family and retained good functional status until eventually succumbing to liver failure from her aggressive, multifocal HCC.
Discussion
HCC may invade major vessels through stromal destruction, with endothelial rupture and formation of tumor thrombus. Alternatively, clusters of tumor cells may be found in the vascular lumen, which are coated with endothelium and thus are protected from initiation of the coagulation cascade. This may occur in the absence of stromal destruction near the tumor periphery and is hypothesized to enhance the propensity for distant metastasis [15] . Indeed, microemboli encapsulated in endothelium were observed herniating into peritumoral vessels and were subsequently able to be isolated from the blood. They may retain viability and metastatic potential upon deposition in the pulmonary and hepatic capillary beds, thus demonstrating a metastatic mechanism independent from epithelial-mesenchymal transition [16] . The detection of endothelium-coated microemboli in adjacent nontumor tissue served as an independent predictor of poor prognosis after resection. Overall survival and the time to recurrence were decreased, in contrast to cases in which uncoated microemboli were observed [17] .
Enhanced metastatic potential of HCC clones that herniate into vessels expressing an endothelial coating can be attributed in part to cloaking of their antigens from the immunosurveillance mechanism. The endothelial coating itself may also contribute, as it provides protection from shear stress, complement proteins, and clotting factors encountered in the circulation. HCC cells secreting an endothelial vascular invasion membrane may skip a number of steps in the cancer evolution pathway, which they would otherwise need to survive independently for long enough to establish bloodborne metastases. This process may be facilitated by HCC expression of angiopoetin-2, which plays a role in the activation of the vascular endothelial growth factor (VEGF) pathway. Angiopoetin-2 expression may enable HCC to package clusters of malignant cells into raft-like endothelial structures and push them into peritumoral vessels [16] . Increased intratumoral pressure from abnormal growth within the neoplasm may facilitate this process, along with other characteristics of the tumor microenvironment such as tissue hypoxia [18] .
Hypoxia drives angiogenesis, characterized by abnormal vascular remodeling and 'leaky' tumor vasculature. This manifests as local hypoxia in underperfused portions of the tumor, in turn upregulating the expression of VEGF. Elevated VEGF expression correlates with propensity for vascular invasion, recurrence after treatment, and is a predictor of poor prognosis. Indeed, VEGF overexpression in cirrhotic livers has been implicated in hepatic carcinogenesis [19] . The positive feedback loop described involving angiogenesis and hypoxia has disastrous implications for patients and is a major contributor to HCC's dreadful prognosis. Sorafenib, purported as a VEGF pathway inhibitor is being deployed in clinical practice for patients with advanced HCC and has been shown to increase overall survival. Interventional oncologic techniques, such as transarterial chemoembolizations, radioembolization, and cryoablation in combination with sorafenib, to transiently normalize tumor vasculature may be employed to treat advanced HCC. Even in the setting of intrahepatic IVC invasion, intermittent flow obstruction using an angioplasty balloon may facilitate palliative cryoablation.
Conclusion
Intravascular cryoablation is possible utilizing an intermittently inflated angioplasty balloon within the IVC. This method provides a technical strategy to overcome the 'thermal sink' phenomenon by causing temporary cessation of the blood flow. Patients with intrahepatic IVC invasion may benefit from this modality, if their neoplasm is not amenable to other ablative, embolization, or surgical methods.
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